Program to prepare for surgery in locally advanced pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial studies an “implementation program” to help patients with locally advanced pancreatic cancer get ready for the next steps after chemotherapy. It may help improve care planning and outcomes for people whose cancer has not grown after initial treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- Your pancreatic cancer has been confirmed by biopsy/pathology
- Your cancer has not progressed on CT scan after at least 4 months of chemotherapy
- You received chemotherapy such as FOLFIRINOX or gemcitabine plus nab-paclitaxel
- Your pancreatic cancer is not metastatic (it has not spread to distant organs) before starting chemotherapy
- Your tumor does not wrap around major blood vessels too extensively (arterial involvement over a certain angle, or major vein blockage)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether surgery can help people with a certain type of pancreatic cancer that is locally advanced but not yet spread. You may join if your cancer has shrunk or stayed stable after at least 4 months of chemotherapy and your medical team thinks surgery is possible.
This trial is testing a new way to treat pancreatic cancer that has spread to nearby tissues but not to distant organs. It uses a tailored plan that may include chemotherapy and possibly surgery. The goal is to see if this personalized approach helps people live longer and better.
This trial tests whether taking chemotherapy for a longer period before surgery can help people with borderline or locally advanced pancreatic cancer. It aims to see if a longer treatment course leads to better outcomes.
This Phase 2 trial tests a chemotherapy plan given before surgery (called “neoadjuvant” treatment) for people with pancreatic adenocarcinoma that looks resectable or borderline resectable on scans. The goal is to see how well this adaptive chemotherapy approach works and whether it can improve outcomes before an operation.
This trial tests giving chemotherapy before any surgery to people with borderline resectable or locally advanced pancreatic cancer. The goal is to shrink the tumor, which may make surgery more successful and improve outcomes.
This trial tests whether adding focused ultrasound (IMD10) to standard chemotherapy helps treat pancreatic cancer that is borderline or locally advanced and cannot be removed by surgery right away. It may shrink the tumor enough to allow surgery later.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.